# A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma

> **NCT03769090** · PHASE3 · COMPLETED · sponsor: **Bond Avillion 2 Development LP** · enrollment: 3132 (actual)

## Conditions studied

- Asthma

## Interventions

- **COMBINATION_PRODUCT:** Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg
- **COMBINATION_PRODUCT:** Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg
- **DRUG:** Albuterol sulfate metered-dose inhaler 180 μg

## Key facts

- **NCT ID:** NCT03769090
- **Lead sponsor:** Bond Avillion 2 Development LP
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-13
- **Primary completion:** 2021-08-19
- **Final completion:** 2022-02-07
- **Target enrollment:** 3132 (ACTUAL)
- **Last updated:** 2022-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03769090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03769090, "A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03769090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*